Premium
THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
Author(s) -
Advani R.,
Bartlett N.L.,
Smith S.M.,
Roschewski M.,
Popplewell L.,
Flinn I.,
Collins G.,
Ghosh N.,
LaCasce A.,
Asch A.,
Kline J.,
Kesevan M.,
Tran T.,
Lynn J.,
Huang J.,
Agoram B.,
Volkmer J.,
Takimoto C.H.,
Chao M.P.,
Mehta A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.57_2629
Subject(s) - rituximab , medicine , refractory (planetary science) , chills , gastroenterology , lymphoma , oncology , neutropenia , chemotherapy , astrobiology , physics